NYSEAMERICAN:BTX - Brooklyn ImmunoTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 875.34 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.72
▼ -0.03 (-4.01%)

This chart shows the closing price for BTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Brooklyn ImmunoTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTX

Analyst Price Target is $7.00
▲ +875.34% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Brooklyn ImmunoTherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 875.34% upside from the last price of $0.72.

This chart shows the closing price for BTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Brooklyn ImmunoTherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/20/2022Maxim GroupLower Price Target$9.00 ➝ $5.00
12/29/2021Cantor FitzgeraldInitiated CoverageOverweight$9.00
10/6/2021Maxim GroupInitiated CoverageBuy$20.00
8/9/2019HC WainwrightReiterated RatingBuy$4.00
7/11/2019HC WainwrightSet Price TargetBuy$4.00
7/3/2019HC WainwrightSet Price TargetBuy$4.00
6/13/2019Raymond JamesInitiated CoverageMkt Perform ➝ Market Perform
5/2/2019HC WainwrightSet Price TargetBuy$4.00
3/18/2019Raymond JamesLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00
2/21/2019HC WainwrightInitiated CoverageBuy ➝ Buy$4.00
2/15/2019Maxim GroupSet Price TargetBuy$3.00
2/7/2019Dawson JamesInitiated CoverageBuy
1/30/2019Maxim GroupReiterated RatingBuy$3.00
1/24/2019Maxim GroupInitiated CoverageBuy ➝ Buy$3.00
12/11/2018CIBCInitiated CoverageOutperform ➝ Outperform$3.50
12/11/2018OppenheimerInitiated CoverageOutperform$3.50
2/2/2018Lake Street CapitalInitiated CoverageBuy ➝ Buy$8.00
6/19/2017LADENBURG THALM/SH SHReiterated RatingBuy$6.00 ➝ $6.50
(Data available from 5/22/2017 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Brooklyn ImmunoTherapeutics logo
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Read More

Today's Range

Now: $0.72
Low: $0.67
High: $0.78

50 Day Range

MA: N/A

52 Week Range

Now: $0.72
Low: $0.67
High: $23.34

Volume

305,411 shs

Average Volume

432,343 shs

Market Capitalization

$41.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Brooklyn ImmunoTherapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Brooklyn ImmunoTherapeutics in the last twelve months: Cantor Fitzgerald, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for BTX.

What is the current price target for Brooklyn ImmunoTherapeutics?

0 Wall Street analysts have set twelve-month price targets for Brooklyn ImmunoTherapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 875.3%.
View the latest price targets for BTX.

What is the current consensus analyst rating for Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTX will outperform the market and that investors should add to their positions of Brooklyn ImmunoTherapeutics.
View the latest ratings for BTX.

How do I contact Brooklyn ImmunoTherapeutics' investor relations team?

Brooklyn ImmunoTherapeutics' physical mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company's listed phone number is (212) 582-1199. The official website for Brooklyn ImmunoTherapeutics is www.biotimeinc.com. Learn More about contacing Brooklyn ImmunoTherapeutics investor relations.